<DOC>
	<DOCNO>NCT00942149</DOCNO>
	<brief_summary>This safety pharmacokinetic study single-dose daptomycin infant &gt; 48 hour &lt; 120 day age suspect systemic infection . The investigator enroll total 24 infant 4 gestational age/postnatal age cohort . Interim analyse perform 3 infant enrol cohort . The investigator anticipate 6 mg/kg daptomycin yield AUC &lt; 740 mch*hr/mL .</brief_summary>
	<brief_title>An Open Label Study Describe Pharmacokinetics Daptomycin Infants</brief_title>
	<detailed_description />
	<mesh_term>Daptomycin</mesh_term>
	<criteria>1 . &gt; 48 hour &lt; 120 day age time daptomycin administration 2 . Sufficient venous access permit administration study medication 3 . Suspected systemic infection appropriate culture ( blood +/ urine/CSF ) obtain within 72 hour study entry 4 . Availability willingness parent/legally authorize representative provide write informed consent 1 . History anaphylaxis attribute daptomycin 2 . Previous participation study 3 . Exposure daptomycin month prior study 4 . Serum creatinine &gt; 1.0 mg/dL 5 . Concomitant administration tobramycin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Infants</keyword>
	<keyword>Daptomycin</keyword>
</DOC>